Search research articles
Contact Us
Filters
Showing results (21-30 of 466) with videos related to
Page
of 47
Sort By:
Journal of Oncology Practice
|
June 13, 2017
Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges
Simone A Edenhofer, Stephan Stilgenbauer
Expert Opinion on Pharmacotherapy
|
March 13, 2020
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
Dirk L Kienle, Stephan Stilgenbauer
Blood
|
June 15, 2023
Richter transformation: epigenetics to blame?
Deyan Y Yosifov, Stephan Stilgenbauer
Leukemia & Lymphoma
|
February 3, 2015
How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Constantine S Tam, Stephan Stilgenbauer
Clinics in Laboratory Medicine
|
November 29, 2011
Genetics of chronic lymphocytic leukemia
Andrea Schnaiter, Daniel Mertens, Stephan Stilgenbauer
Haematologica
|
October 6, 2011
Chronic lymphocytic leukemia--genomics lead the way
Daniel Mertens, Lars Bullinger, Stephan Stilgenbauer
Oncology Research and Treatment
|
February 19, 2016
Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia
Eugen Tausch, Daniel Mertens, Stephan Stilgenbauer
Best Practice & Research. Clinical Haematology
|
August 21, 2007
Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia
Thorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer
Frontiers in Oncology
|
February 1, 2021
Telomere Dysfunction in Chronic Lymphocytic Leukemia
Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Oncology Research and Treatment
|
April 17, 2015
Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody
Valentin Goede, Christian Klein, Stephan Stilgenbauer
Page
of 47
Search research articles
Search
Showing results (21-30 of 466) with videos related to
Sort By:
Page
of 47
Journal of Oncology Practice
|
June 13, 2017
Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges
Simone A Edenhofer, Stephan Stilgenbauer
Expert Opinion on Pharmacotherapy
|
March 13, 2020
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
Dirk L Kienle, Stephan Stilgenbauer
Blood
|
June 15, 2023
Richter transformation: epigenetics to blame?
Deyan Y Yosifov, Stephan Stilgenbauer
Leukemia & Lymphoma
|
February 3, 2015
How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Constantine S Tam, Stephan Stilgenbauer
Clinics in Laboratory Medicine
|
November 29, 2011
Genetics of chronic lymphocytic leukemia
Andrea Schnaiter, Daniel Mertens, Stephan Stilgenbauer
Haematologica
|
October 6, 2011
Chronic lymphocytic leukemia--genomics lead the way
Daniel Mertens, Lars Bullinger, Stephan Stilgenbauer
Oncology Research and Treatment
|
February 19, 2016
Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia
Eugen Tausch, Daniel Mertens, Stephan Stilgenbauer
Best Practice & Research. Clinical Haematology
|
August 21, 2007
Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia
Thorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer
Frontiers in Oncology
|
February 1, 2021
Telomere Dysfunction in Chronic Lymphocytic Leukemia
Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Oncology Research and Treatment
|
April 17, 2015
Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody
Valentin Goede, Christian Klein, Stephan Stilgenbauer
Page
of 47